Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Trial Profile

Phase III, open-label, long-term safety study of topical RT 001 [botulinum toxin A] for the treatment of lateral canthal lines

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 13 May 2015 According to a Revance Therapeutics media release, status changed from recruiting to active, no longer recruiting.
    • 26 May 2014 New trial record
    • 13 May 2014 Interim data is expected in 2015, according to a Revance Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top